Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
publication

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?


Wei, A.H. et al.
Cancer Discovery (2019)
Abstract

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias..



Authors

Wei, A.H., Roberts, A.W.



VIEW

publication
Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue
Sharma R
Blood (2021)
publication
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao Y
Nature (2021)
publication
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Sahoo S.S.
Nature Medicine (2021)
publication
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O.
Cancer Cell (2021)
REQUEST QUOTE